Opexa therapeutics: Corporate Presentation (Opexa Therapeutics) - Aug 21, 2014 - Anticipated completion of P2b Abili-T immune monitoring trial for secondary progressive multiple sclerosis in H2 2016
Anticipated trial completion date • Multiple Sclerosis
|